---
title: "NBSE.ESC.US (NBSE.ESC.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBSE.ESC.US/news.md"
symbol: "NBSE.ESC.US"
name: "NBSE.ESC.US"
parent: "https://longbridge.com/en/quote/NBSE.ESC.US.md"
datetime: "2026-03-04T18:22:17.811Z"
locales:
  - [en](https://longbridge.com/en/quote/NBSE.ESC.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBSE.ESC.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBSE.ESC.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NBSE.ESC.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NBSE.ESC.US/news.md)


# NBSE.ESC.US (NBSE.ESC.US) — Related News

### [Affinia Therapeutics Granted FDA Fast Track Designation For Aftx-201 As A Treatment For People Living With Bag3-Associated Dilated Cardiomyopathy (Dcm)](https://longbridge.com/en/news/277780747.md)
*2026-03-04T12:45:42.000Z*
> March 4 (Reuters) - Affinia Therapeutics Inc:* AFFINIA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR AFTX-201 AS A

### [XORTX Calls March 24, 2026 Shareholder Meeting to Vote on Share Consolidation and Governance Matters](https://longbridge.com/en/news/277648986.md)
*2026-03-03T15:29:28.000Z*
> XORTX Therapeutics Inc. has scheduled its annual and special shareholders’ meeting for March 24, 2026, to discuss financ

### [Shield Therapeutics (LON:STX) Stock Price Passes Below Fifty Day Moving Average   - Time to Sell?](https://longbridge.com/en/news/277299255.md)
*2026-02-28T11:31:27.000Z*
> Shield Therapeutics (LON:STX) stock price fell below its 50-day moving average of GBX 10.47, trading as low as GBX 9.50 

### [Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome](https://longbridge.com/en/news/277033094.md)
*2026-02-26T11:38:09.000Z*
> Mahzi Therapeutics has initiated its Phase I/II UNITE study by dosing the first patient with MZ-1866, a gene therapy tar

### [Egetis Therapeutics FY Revenue At SEK 62.3 Million, Below IBES Estimate](https://longbridge.com/en/news/276991916.md)
*2026-02-26T06:23:44.000Z*
> Feb 26 (Reuters) - Egetis Therapeutics AB (publ) (EGTX.ST) :FY REVENUE SEK 62.3 MILLION VERSUS. IBES ESTIMATE SEK 67.2 M

### [17:31 ETDrug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight](https://longbridge.com/en/news/276796435.md)
*2026-02-24T22:32:17.000Z*
> DelveInsight forecasts significant growth in the drug-resistant epilepsy market from 2025 to 2034, driven by rising prev

### [Nykode Therapeutics Announces New Interim Data from the VB-C-03 Trial Showing Encouraging Anti-Tumor Activity and Tolerability of Abi-suva (VB10.16)](https://longbridge.com/en/news/276719829.md)
*2026-02-24T10:45:01.000Z*
> Nykode Therapeutics announced interim data from the VB-C-03 trial, showing an objective response rate (ORR) of 38.5% for

### [Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board | AKTX Stock News](https://longbridge.com/en/news/276608840.md)
*2026-02-23T05:50:00.000Z*
> Akari Therapeutics has appointed Dr. Olga Anczukow, an expert in RNA biology and cancer research, to its Scientific Advi

### [08:40 ET"Would You Clone Yourself for a Cure?" Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using 'Human Cloning' Technology](https://longbridge.com/en/news/276607620.md)
*2026-02-23T13:42:17.000Z*
> Clonell Therapeutics, Inc. has released a white paper detailing its innovative 'Therapeutic Cloning' technology aimed at

### [Rakovina Therapeutics Upsizes Financing to Up to $2 Million](https://longbridge.com/en/news/276599869.md)
*2026-02-23T12:14:00.000Z*
> Rakovina Therapeutics has increased its financing to approximately $2 million from $1.5 million. The financing includes